BUSINESS COMBINATION AND DECONSOLIDATION OF SUBSIDIARY (Details 5) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net revenues	$ 1,359	$ 192	$ 4,939	$ 741
Net loss	(4,343)	$ (2,751)	(8,835)	$ (14,144)
Cure Pharmaceutical [Member]
Net revenues	192		741
Net loss	$ (2,751)		$ (14,144)
Net loss attributable to Cure per common share, basic	$ (0.07)		$ (0.32)
Net loss attributable to Cure per common share diluted	$ (0.07)		$ (0.32)
Pro forma Adjustment [Member]
Net revenues	$ 0		$ 0
Net loss	0		0
Consolidated Pro Forma [Member]
Net revenues	1,936		6,426
Net loss	$ (3,721)		$ (15,471)
Net loss attributable to Cure per common share, basic	$ (0.07)		$ (0.30)
Net loss attributable to Cure per common share diluted	$ (0.07)		$ (0.30)
Sera Labs [Member]
Net revenues	$ 1,744		$ 5,685
Net loss	$ (970)		$ (1,327)
Net loss attributable to Cure per common share, basic	$ (0.08)		$ (0.11)
Net loss attributable to Cure per common share diluted	$ (0.08)		$ (0.11)